Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 1
1968 1
1969 2
1970 5
1971 3
1972 3
1974 1
1975 2
1976 3
1977 5
1979 15
1980 14
1981 14
1982 7
1983 6
1984 5
1985 2
1986 1
1987 4
1988 7
1989 8
1990 5
1991 12
1992 10
1993 5
1994 4
1995 7
1996 10
1997 13
1998 7
1999 7
2000 5
2001 2
2002 6
2003 5
2004 15
2005 13
2006 9
2007 9
2008 8
2009 15
2010 12
2011 9
2012 9
2013 9
2014 3
2015 4
2016 7
2017 6
2018 9
2019 7
2020 7
2021 7
2022 5
2023 5
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV, Soler C, Fevre C, Arnaud I, Bretaudeau L, Gabard J. Jault P, et al. Lancet Infect Dis. 2019 Jan;19(1):35-45. doi: 10.1016/S1473-3099(18)30482-1. Epub 2018 Oct 3. Lancet Infect Dis. 2019. PMID: 30292481 Clinical Trial.
Eligible participants were randomly assigned (1:1) by use of an interactive web response system to a cocktail of 12 natural lytic anti-P aeruginosa bacteriophages (PP1131; 1 10(6) plaque-forming units [PFU] per mL) or standard of care (1% sulfadiazine silver emulsion cream …
Eligible participants were randomly assigned (1:1) by use of an interactive web response system to a cocktail of 12 natural lytic anti-P aer …
Innovative Burn Treatment Using Tilapia Skin as a Xenograft: A Phase II Randomized Controlled Trial.
Lima Júnior EM, De Moraes Filho MO, Costa BA, Rohleder AVP, Sales Rocha MB, Fechine FV, Forte AJ, Alves APNN, Silva Júnior FR, Martins CB, Mathor MB, Moraes MEA. Lima Júnior EM, et al. J Burn Care Res. 2020 May 2;41(3):585-592. doi: 10.1093/jbcr/irz205. J Burn Care Res. 2020. PMID: 31900475 Clinical Trial.
It was found that in participants treated with tilapia skin, complete reepithelialization occurred in significantly fewer days; reported pain intensity was lower (study arms B and C), the amount of anesthetics/analgesics required was lower (study arms B and C), and the necessity …
It was found that in participants treated with tilapia skin, complete reepithelialization occurred in significantly fewer days; reported pai …
Nile Tilapia Fish Skin-Based Wound Dressing Improves Pain and Treatment-Related Costs of Superficial Partial-Thickness Burns: A Phase III Randomized Controlled Trial.
Lima Júnior EM, de Moraes Filho MO, Costa BA, Fechine FV, Vale ML, Diógenes AKL, Neves KRT, Uchôa AMDN, Soares MFADN, de Moraes MEA. Lima Júnior EM, et al. Plast Reconstr Surg. 2021 May 1;147(5):1189-1198. doi: 10.1097/PRS.0000000000007895. Plast Reconstr Surg. 2021. PMID: 33890902 Clinical Trial.
BACKGROUND: In a phase II study comparing Nile tilapia fish skin to silver sulfadiazine cream for outpatient management of superficial partial-thickness burns, the fish skin decreased reepithelialization time (average reduction, 1.43 days), dressing changes (average reduct …
BACKGROUND: In a phase II study comparing Nile tilapia fish skin to silver sulfadiazine cream for outpatient management of superficia …
Efficacy and costs of nanocrystalline silver dressings versus 1% silver sulfadiazine dressings to treat burns in adults in the outpatient setting: A randomized clinical trial.
Moreira SS, Camargo MC, Caetano R, Alves MR, Itria A, Pereira TV, Lopes LC. Moreira SS, et al. Burns. 2022 May;48(3):568-576. doi: 10.1016/j.burns.2021.05.014. Epub 2021 Jun 1. Burns. 2022. PMID: 34688520 Clinical Trial.
However, the evidence regarding their efficacy and cost-consequences compared to well-established treatments, such as 1% silver sulfadiazine, is still scarce. OBJECTIVE: To determine the efficacy, safety, and costs of nanocrystalline silver dressings compared to 1% silver …
However, the evidence regarding their efficacy and cost-consequences compared to well-established treatments, such as 1% silver sulfadiaz …
The impact of an open-label design on human amniotic membranes vs. silver sulfadiazine dressings for second-degree burns: a randomized controlled clinical trial.
Moghimi MH, Salehian M, Abdi M, Tahrekhani M, Safaei A, Kamali K. Moghimi MH, et al. BMC Surg. 2024 Oct 14;24(1):309. doi: 10.1186/s12893-024-02554-5. BMC Surg. 2024. PMID: 39396946 Free PMC article. Clinical Trial.
The present study aimed to compare the outcomes of using human amniotic membrane (hAM) dressings and conventional silver sulfadiazine (SSDZ) ointment dressings in the management of second-degree burn wounds. METHODS: Fifty patients who participated in this clinical trial w …
The present study aimed to compare the outcomes of using human amniotic membrane (hAM) dressings and conventional silver sulfadiazine …
Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial.
Wei Y, Li Y, Li X, Zhao Y, Xu J, Wang H, Rong X, Xiong J, Chen X, Luo G, Lv G, Lin C, Han C, Yu H, Zhang Y, Tang S, Fan Y, Tu J, Xia C, Zu H, Liu W, Liu C, Liu J, Zhang B, Nong Q, Li T, Wang L, Song G, Su Y, Chen Z, Lai W, Fu Y, Yu J, Zhang P, Yang W, Yao G, Zhang H, Fan K, Dong H, Chen Y, Wu J; PL-5 Investigators. Wei Y, et al. JAMA Netw Open. 2024 Jun 3;7(6):e2415310. doi: 10.1001/jamanetworkopen.2024.15310. JAMA Netw Open. 2024. PMID: 38861260 Free PMC article. Clinical Trial.
One group received treatment with 2% peceleganan spray (n = 381) and the other with 1% silver sulfadiazine (SSD) cream (n = 189). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the clinical efficacy rate (the number of patients fulfilling the criteria for eff …
One group received treatment with 2% peceleganan spray (n = 381) and the other with 1% silver sulfadiazine (SSD) cream (n = 189). MAI …
To compare the effect of sea buckthorn and silver sulfadiazine dressing on period of wound healing in patients with second-degree burns: A randomized triple-blind clinical trial.
Abdullahzadeh M, Shafiee S. Abdullahzadeh M, et al. Wound Repair Regen. 2021 Sep;29(5):732-740. doi: 10.1111/wrr.12916. Epub 2021 Apr 1. Wound Repair Regen. 2021. PMID: 33792111 Clinical Trial.
We conducted this clinical trial to evaluate the period of wound healing with sea buckthorn dressings for the second-degree burns and compare the results with 1% silver sulfadiazine (SSD) dressings. This randomized triple-blind clinical trial was conducted in a hospital in …
We conducted this clinical trial to evaluate the period of wound healing with sea buckthorn dressings for the second-degree burns and compar …
Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis.
Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, Yaseri M, Peyman GA. Soheilian M, et al. Ophthalmology. 2011 Jan;118(1):134-41. doi: 10.1016/j.ophtha.2010.04.020. Epub 2010 Aug 12. Ophthalmology. 2011. PMID: 20708269 Clinical Trial.
INTERVENTION: The IVCD group received 1 to 3 injection(s) of 1 mg intravitreal clindamycin and 400 mug dexamethasone, and the CT group received 6 weeks of treatment with pyrimethamine and sulfadiazine plus prednisolone. Antitoxoplasmosis antibodies (immunoglobulin [Ig] M a …
INTERVENTION: The IVCD group received 1 to 3 injection(s) of 1 mg intravitreal clindamycin and 400 mug dexamethasone, and the CT group recei …
Efficacy and Safety of PL-5 (Peceleganan) Spray for Wound Infections: A Phase IIb Randomized Clinical Trial.
Wei Y, Wu J, Chen Y, Fan K, Yu X, Li X, Zhao Y, Li Y, Lv G, Song G, Rong X, Lin C, Wang H, Chen X, Zhang P, Han C, Zu H, Liu W, Zhang Y, Liu C, Su Y, Zhang B, Sun B, Wang L, Lai W, Liu J, Xia C, Ji G, Zhu F, Yu J, Ahemaiti A, Dong H, Chen M; PL-5 Investigators. Wei Y, et al. Ann Surg. 2023 Jan 1;277(1):43-49. doi: 10.1097/SLA.0000000000005508. Epub 2022 Jul 4. Ann Surg. 2023. PMID: 35781462 Free PMC article. Clinical Trial.
METHODS: We conducted a multicenter, open-label, randomized, controlled phase IIb clinical trial to evaluate the efficacy and safety of PL-5 spray, as compared with silver sulfadiazine, in patients with skin wound infections. The primary efficacy outcome was the clinical e …
METHODS: We conducted a multicenter, open-label, randomized, controlled phase IIb clinical trial to evaluate the efficacy and safety of PL-5 …
Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis.
Shikanai-Yasuda MA, Benard G, Higaki Y, Del Negro GM, Hoo S, Vaccari EH, Gryschek RC, Segurado AA, Barone AA, Andrade DR. Shikanai-Yasuda MA, et al. Med Mycol. 2002 Aug;40(4):411-7. doi: 10.1080/mmy.40.4.411.417. Med Mycol. 2002. PMID: 12230222 Clinical Trial.
Forty-two patients with active paracoccidioidomycosis were randomized to receive itraconazole (50-100 mg d(-1)), ketoconazole (200-400 mg d(-1)) or sulfadiazine (100-150 mg kg d(-1) up to 6 g d(-1)) for 4-6 months, followed by slow release sulfa until negativity of serolog …
Forty-two patients with active paracoccidioidomycosis were randomized to receive itraconazole (50-100 mg d(-1)), ketoconazole (200-400 mg d( …
359 results